Expanding the Cancer Neoantigen Peptide Repertoire beyond In silico Tools

doi:10.33696/cancerimmunol.3.039

Cited by 1 publication

(1 citation statement)

References 48 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The APCs can be programmed for expression of pMHC using vector-based approaches (62,63) or modern CRISPR-based genome-editing techniques (64,65). Off-target toxicity issues may be resolved by testing in humanized animal models or using cell reprogramming tools to generate different types of tissues for using them as antigen-bearing surrogates or organoids (66).…”

Section: Tcr Mimic Antibodies In Cancer Immunotherapymentioning

confidence: 99%

Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies

et al. 2021

View full text Add to dashboard Cite

Transcription factor and oncosuppressor protein p53 is considered as one of the most promising molecular targets that remains a high-hanging fruit in cancer therapy. TP53 gene encoding the p53 protein is known to be the most frequently mutated gene in human cancers. The loss of transcriptional functions caused by mutations in p53 protein leads to deactivation of intrinsic tumor suppressive responses associated with wild-type (WT) p53 and acquisition of new pro-oncogenic properties such as enhanced cell proliferation, metastasis and chemoresistance. Hotspot mutations of p53 are often immunogenic and elicit intratumoral T cell responses to mutant p53 neoantigens, thus suggesting this protein as an attractive candidate for targeted anti-cancer immunotherapies. In this review we discuss the possible use of p53 antigens as molecular targets in immunotherapy, including the application of T cell receptor mimic (TCRm) monoclonal antibodies (mAbs) as a novel powerful approach.

show abstract